AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

AstraZeneca (NASDAQ:AZN) announced Thursday that gefurulimab, its experimental injectable for generalized myasthenia gravis, ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

AstraZeneca has bagged a win for its rare disease pipeline, with its Phase III trial of gefurulimab demonstrating the drug’s ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

The landscape of gMG treatment is rapidly evolving, said John Morren, MD, of the Cleveland Clinic. The traditional approach to managing gMG involves broad immunosuppressive therapies, but emerging ...

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially ...